Christopher Wallis, MD, PhD, FRCSC

Christopher Wallis, MD, PhD, FRCSC
Assistant Professor, Division of Urology, University of Toronto
Urologic Oncologist, Division of Urology, Mount Sinai Hospital and University Health Network

Articles by Christopher Wallis, MD, PhD, FRCSC

Oliver Sartor, MDRLT | December 4, 2023
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
View More
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | November 30, 2023
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. George and Wallis discuss applications and counseling patients on focal therapy, as well as post-treatment follow-up.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 1, 2023
Drs. Murray and Wallis discuss optimal patient selection, size criteria, and surgical ablation and chemoablation together.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
Alberto Bossi, MDASCO 2023 | August 23, 2023
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
Petros Grivas, MD, PhDUpper Tract Urothelial Carcinoma | July 24, 2023
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
Petros Grivas, MD, PhDUpper Tract Urothelial Carcinoma | July 24, 2023
Approaching perioperative systemic therapy in upper and lower tract disease, including neoadjuvant and adjuvant therapy.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | July 24, 2023
Assessing the treatment landscape in UTUC and how many different patient biomarkers influence treatment integration.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | August 15, 2023
A continuation of the discussion on UTUC vascular-targeted photodynamic therapy as a way of nephron-sparing for patients.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | July 24, 2023
Breaking down the differences in "high risk" and "low risk" stratification in the UTUC guideline, and other biomarkers.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | July 24, 2023
A summary of the therapeutic strategies available for avoiding surgery for UTUC, as well as other management considerations.
Karim Fizazi, MD, PhDASCO 2023 | August 1, 2023
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Brian Rini, MD, FASCOASCO 2023 | June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
Oncology BrothersASCO 2023 | June 6, 2023
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
Jérémie Calais, MD, MScASCO 2023 | June 4, 2023
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.